S&P/ASX 200 Index (ASX: XJO) shares are flat at 9,072 points as earnings season continues on Tuesday.

The benchmark index is experiencing a strong start to the new financial year.

Just seven weeks into FY27, and the ASX 200 is already up 3.3%.

That compares to a 2.8% rise over the whole of FY26 (total return, including dividends, of 7%).

Two of the drivers are the healthcare and technology sectors, which are recovering from extended slumps.

Healthcare shares are up 17% so far in FY27, while tech is up 8%.

An increasing number of Australians are turning to ASX exchange-traded funds (ETFs) to make investing easier.

ASX ETFs provide exposure to a basket of stocks, thereby enabling great diversification in a single trade.

They’re also an easy way to gain exposure to international shares via our local exchange.

In today’s rising market, Andrew Wielandt from DP Wealth Advisory has recommended two ETFs to buy.

On The Bull this week, Wielandt explains his recommendations.

Betashares Global Royalties ETF (ASX: ROYL)

The ROYL ETF is $13.89, up 0.3% on Tuesday and up 15% over 12 months.

Wielandt explained his buy rating:

ROYL is a diverse exchange traded fund operating across a number of countries, including the United States, Canada, Brazil and Denmark.

It holds about 40 companies, with investments including ARM Holdings PLC, Texas Pacific Land Corporation and Wheaton Precious Metals at August 11, 2026.

ROYL focuses on companies earning royalty and intellectual property income.

What appeals is relatively steady returns compared to other cyclical investments.

The company posted a return of 15.59 per cent after fees in the past 12 months to July 31, 2026.

Munro Climate Change Leaders Fund Active ETF (ASX: MCCL)

The MCCL ETF is $18.14, up 0.9% today and up 7% over 12 months.

Wielandt discusses his buy recommendation:

This exchange traded fund holds a concentrated portfolio of companies aiming to benefit from decarbonisation during the next decade.

The ETF holds between 15 and 25 positions involved in clean energy, clean transport and energy efficiency.

The fund posted a return of 16.9 per cent for the 12 months to July 31, 2026.

However, given its highly concentrated nature, it’s important to note that returns can be volatile.

In our view, MCCL can also be considered an investment in the future and can be part of a balanced portfolio.

I hold MCCL in my self-managed super fund (SMSF).

Best ASX ETFs of FY26

Check out the 6 best ETFs holding ASX shares of FY26 here.

You can also review the 6 best international ETFs of FY26 here.

The post 2 ASX ETFs to buy as the market gathers strength: expert appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Aristocrat, Telstra, ANZ shares
• Why is everyone talking about CSL, Pro Medicus and BHP shares on Tuesday?
• How to find ASX shares that Warren Buffett might buy
• Here’s what brokers tip for Wesfarmers shares over the next 12 months
• How much do I need in my superannuation to earn $50,000 per year in passive income?

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Arm Holdings. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) shares are up 0.4% to 9,105.1 points on Tuesday.

As earnings season continues, top broker Morgans has issued some new ratings on ASX 200 shares.

Let’s check them out.

Aristocrat Leisure Ltd (ASX: ALL)

The Aristocrat Leisure share price is $63.30, down 1.9% today and down 10.3% over 12 months. 

Morgans has downgraded this ASX 200 consumer discretionary share from buy to accumulate.

The broker said: 

We attended the Australasian Gaming Expo (AGE) in Sydney last week, which serves as the key annual showcase for the region’s major slot machine manufacturers.

Alongside meetings with other suppliers and operators, we attended a Q&A session with ALL management and took a guided tour of its product.

Land-based momentum looks solid to us. ALL continues to push new titles onto its existing cabinets while laying the groundwork for the next wave of hardware and the content that comes with it.

Despite the stock trading on c.23x forward PER with a c.2% yield, we continue to see upside potential given the strong momentum entering peak season.

However, following recent share price strength, we revise our rating to Accumulate with a 12-month target price of A$70.00 (prev. A$67.00).

Telstra Group Ltd (ASX: TLS)

The Telstra share price is $4.74, down 1.5% today and down 4% over 12 months. 

Telstra shares fell 5.2% after the telco released its full-year FY26 results last Thursday.

Morgans has a hold rating on this ASX 200 telecommunications share. 

The broker said: 

TLS’s FY26 result and FY27 guidance were largely as expected, with FY26 itself coming in at the middle-to-top end of guidance.

This largely in-line result wasn’t enough for the marginal buyer and TLS shares ended the day down 3%.

We lift FY27/28 EPS by ~4%. Our target price is reduced to $5 as we remove our previously applied premium to valuation.

Hold recommendation retained.

ANZ Group Holdings Ltd (ASX: ANZ)

The ANZ share price is $37.45, down 1.1% today and up 15% over 12 months. 

ANZ shares rose 4.5% after the bank released its 3Q FY26 update last Thursday.

Morgans maintained its trim rating on this ASX 200 bank share. 

The broker said: 

Underlying earnings growth, delivery of cost decline and low bad debts were a feature of the trading update, with lifting momentum behind revenue growth.

Forecast changes are immaterial. 12-month target price reset to $33.53/s.

TRIM retained, with potential TSR at current prices of c.-9% (including 4.4% yield).

The post Buy, hold, sell: Aristocrat, Telstra, ANZ shares appeared first on The Motley Fool Australia.

More reading

• How much do I need in my superannuation to earn $50,000 per year in passive income?
• How much could the Telstra share price rise in the next year?
• These ASX 200 shares could generate $10,000 per year in passive income
• Reporting season half-time report: 5 lessons from August so far
• How much do I need to retire on $100,000 a year at 60?

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Telstra Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd (ASX: CSL), Pro Medicus Ltd (ASX: PME), and BHP Group Ltd (ASX: BHP) shares are turning heads today.

In morning trade on Tuesday, all three of the S&P/ASX 200 Index (ASX: XJO) heavyweights are charging ahead of the 0.1% gains posted by the benchmark index.

Here’s what’s piquing investor interest.

BHP shares jump on 30% profit surge

BHP shares are leaping higher today, up 3.1% and changing hands for $64.12 apiece.

This follows the release of the ASX 200 mining giant’s full-year FY 2026 results.

Among the highlights that look to have investors reaching for their buy buttons, BHP reported a 15% year-on-year increase in revenue to US$58.8 billion. And underlying earnings before interest, taxes, depreciation and amortisation (EBITDA) of US$32.9 billion were up 27%.

The mining giant also achieved a 17% increase in its operating cash flow to US$21.8 billion.

On the bottom line, BHP shares are catching tailwinds with the miner reporting a 30% increase in underlying profit to US$13.2 billion.

On the passive income front, FY 2026 saw US$8.7 billion in dividends determined, equivalent to US$1.72 per share for a 66% payout ratio.

Pro Medicus shares leap on earnings increase

Like BHP shares, Pro Medicus shares are charging higher today following the release of the company’s own FY 2026 results.

Shares in the ASX 200 health imaging company are up a whopping 10.8% at the time of writing, changing hands for $194.78

Investors are piling into Pro Medicus shares after the company reported a 22.9% year-on-year increase in revenue to $261.7 million. And underlying earnings before interest and tax (EBIT) of $196.1 million were up 24.4% from FY 2025.

This helped drive a 24.1% increase in the company’s underlying net profit after tax (NPAT) to $144.7 million.

Pro Medicus also increased its cash and financial assets by 19.7% over the year to $252.3 million.

And the company’s final fully-franked dividend of 37 cents per share is up 23.3% from last year’s payout.

Which brings us to…

CSL shares rocket on profit outlook

Joining Pro Medicus and BHP shares in turning heads – and rocketing higher – today we find CSL.

Shares in the ASX 200 biotech giant are up an impressive 15.4% at the time of writing, trading for $155.37 each. This strong outperformance also follows on CSL’s full-year earnings results.

CSL shares are shooting higher despite the company reporting a 1% year-on-year decline in revenue to US$15.8 billion. And underlying NPATA of US$3.1 billion was down 2% from FY 2025.

Still, management declared a final dividend of US$1.62 per share, in line with last year’s payout.

The big uplift in CSL shares today looks to be driven by the more positive outlook for FY 2027.

“FY26 has been a year of reset. We have taken decisive action and created a clear path to return to sustainable growth,” CSL interim CEO Gordon Naylor said.

Management is forecasting steady revenue in the financial year ahead, while underlying NPAT is forecast to grow by around 5%.

The post Why is everyone talking about CSL, Pro Medicus and BHP shares on Tuesday? appeared first on The Motley Fool Australia.

More reading

• How to find ASX shares that Warren Buffett might buy
• How much do I need in my superannuation to earn $50,000 per year in passive income?
• How many BHP shares do I need to buy for $1,000 per month of passive income?
• Pro Medicus FY26: Strong earnings growth and higher dividend
• BHP Group posts record FY26 earnings and flags copper-led future

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended BHP Group, CSL, and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.